Navigation Links
Pegloticase BLA Filing Accepted for Priority Review by FDA
Date:12/29/2008

ANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding our BLA filing with the FDA, a potential Advisory Committee, approval of the BLA, preparation for commercialization of pegloticase, the efficacy and safety of pegloticase and the market for pegloticase, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our current assessment of the Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of pegloticase and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of pegloticase; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
2. Barrs BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA
3. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
4. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
5. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
6. KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
7. Corporate Parent Hospital Partners of America Files Voluntary Chapter 11 Petition; Filings do not Include any Hospital Facilities
8. VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
9. Wound Management Technologies, Inc. Announces Filing of a 510K
10. Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase)
11. Statement Regarding the Filing of Signatures to Put the Human Embryo Stem Cell Issue on the November Statewide Ballot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
(Date:3/28/2015)... Lately the student-athlete experience has undergone ... around the NCAA. In a March episode of ... a spectrum of universities and sports shed light on ... panel consists of athletes who have competed for universities ... and field, baseball, and volleyball. They discuss the value ...
(Date:3/28/2015)... Virginia (PRWEB) March 28, 2015 ARDX will ... 28th from 12pm -3pm at the Chesapeake Conference Center in ... by sponsoring an empowering event for women in the Hampton ... Weaving the Stories of Women’s Lives. Women grow stronger ... from each other. This year the WWC™ theme is ...
(Date:3/27/2015)... Long Island, NY (PRWEB) March 27, 2015 ... objective, cancer-focused training and business criteria for the spa ... and services to clients who have experienced or are ... of the global Spafinder Wellness 365® Network, will be ... Spafinder.com and recognized as a provider of safe, therapeutic ...
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... By Serena Gordon HealthDay Reporter , THURSDAY, ... four new studies suggest that you could benefit from longer ... done at home or at a dialysis center, but it ... rates and improve quality of life, according to the research ...
... Voluminous research literature attests to the multiple negative ... health and development of children. In contrast, there is ... fathers according to a follow up study by NYU ... edition of Maternal and Child Health Journal. ...
... Doheny HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay ... reduce stroke risk, new research suggests. Diets rich in ... in other studies, but researchers weren,t sure why. For this ... citrus fruits and found a winner. "These data provide ...
... Dotinga HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay ... of those known to be infected, actually struck many more ... analysis finds. The actual fatality rate of the H5N1 ... that millions of people may have been infected over the ...
... B, AB or O. You may even know if you,re ... type? Or the Junior blood type? Positive or negative? Most ... knowledge could be "a matter of life and death," says ... problems due to Langereis and Junior blood types are rare ...
... , THURSDAY, Feb. 23 (HealthDay News) -- ... and emergency department visits, improved patient outcomes and saved ... study. Researchers examined the impact of the Community ... families, developed and implemented in 2005 by a team ...
Cached Medicine News:Health News:More Kidney Dialysis Is Better, Research Finds 2Health News:More Kidney Dialysis Is Better, Research Finds 3Health News:Characteristics of fathers with depressive symptoms 2Health News:Characteristics of fathers with depressive symptoms 3Health News:Citrus Fruits May Lower Women's Stroke Risk 2Health News:Citrus Fruits May Lower Women's Stroke Risk 3Health News:'Bird' Flu May Be More Common in Humans, But Less Deadly 2Health News:Blood mystery solved 2Health News:Blood mystery solved 3Health News:Home-Visit Program May Improve Child's Asthma 2
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the reporting of data from ... Hydrochloride for Injection with the Delcath Hepatic Delivery ... presentation at the Society of Surgical Oncology (SSO) ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
(Date:3/26/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... on Omega-3 therapies for cardiovascular disease and overall health, ... common shares of the Corporation (the "Common Shares"). The ... of December 5 th , 2014 to March 4 ... is due on or before April 1, 2015. Interest ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... Oct. 27 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... and $126.4 million for the second quarter and first ... million and $230.5 million, respectively, during the corresponding periods ... lower for the second quarter and first six months ...
... 27 Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... financial results before the market opens on Tuesday, November 10, ... be held on Tuesday, November 10, 2009 at 10:00 a.m. ... the call, please dial 888-417-8462 (for U.S. callers) or 719-457-2552 ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010 7Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009 2
The WatchMate MR model displays multiple alarms locally without individual identification, but ID numbers and names can be displayed at a central station. Alarms may be cleared locally under password...
... Services is a Web-based and RFID-enabled location ... and measure patient flow and utilization of ... to discharge. AgileTrac collects patient information including ... your patient might experience. This information is ...
... To the network of door controllers, ... regular intervals throughout the coverage area. These ... Pulsing tags. Although similar in size and ... tag used with RoamAlert ECO and RoamAlert ...
... positioning solution (IPS) enables ... and when equipment, staff ... care processes. This time-stamped ... that hospitals can use ...
Medicine Products: